Precigen, Inc.

NasdaqGS:PGEN Stock Report

Market Cap: US$1.4b

Precigen Balance Sheet Health

Financial Health criteria checks 2/6

Precigen has a total shareholder equity of $20.2M and total debt of $93.5M, which brings its debt-to-equity ratio to 462.2%. Its total assets and total liabilities are $138.6M and $118.4M respectively.

Key information

462.16%

Debt to equity ratio

US$93.52m

Debt

Interest coverage ration/a
CashUS$56.25m
EquityUS$20.24m
Total liabilitiesUS$118.39m
Total assetsUS$138.63m

Recent financial health updates

Analysis Article Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article Jul 18

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Recent updates

Seeking Alpha May 21

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

Summary Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight cash, high burn, and future margin compression raise execution risk. Papzimeos momentum is positive, yet a lack of patient-level data and potential for pent-up demand clouds true organic growth visibility. Downgrade PGEN to Hold: risk-reward has contracted, and downside risk looms if Papzimeos underdelivers relative to already-baked-in expectations. Read the full article on Seeking Alpha
Seeking Alpha Feb 28

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking Alpha
Seeking Alpha Feb 10

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking Alpha
Analysis Article Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha Jan 20

Precigen: RRP Targeting With AdenoVerse Technology Platform

Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking Alpha
Analysis Article Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article Jul 18

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article May 15

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

One thing we could say about the analysts on Precigen, Inc. ( NASDAQ:PGEN ) - they aren't optimistic, having just made...

Financial Position Analysis

Short Term Liabilities: PGEN's short term assets ($101.7M) exceed its short term liabilities ($21.1M).

Long Term Liabilities: PGEN's short term assets ($101.7M) exceed its long term liabilities ($97.3M).


Debt to Equity History and Analysis

Debt Level: PGEN's net debt to equity ratio (184.2%) is considered high.

Reducing Debt: PGEN's debt to equity ratio has increased from 99.8% to 462.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGEN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/05 04:41
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Derik de BruinBofA Global Research
Justin WalshB. Riley Securities, Inc.